SCHEDULE 13G: T. Rowe Price Associates Discloses 5.2% Stake in Soleno Therapeutics Inc.
Beneficial Ownership Disclosure
T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting a 5.2% beneficial ownership stake in Soleno Therapeutics Inc. as of March 31, 2025.
Summary
- T. Rowe Price Associates, Inc. has reported beneficial ownership of 2,400,788 shares of Soleno Therapeutics Inc. common stock.
- This ownership represents 5.2% of the total outstanding common stock of Soleno Therapeutics Inc.
- The filing indicates that T. Rowe Price Associates, Inc. holds sole voting power over 2,379,067 shares and sole dispositive power over 2,400,418 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive. While a Schedule 13G is a routine compliance filing, the disclosure of a significant stake by a major institutional investor like T. Rowe Price can be viewed favorably by the market as a sign of confidence in the company.
Positives
- The disclosure of a significant stake by a reputable institutional investor like T. Rowe Price Associates, Inc. can be interpreted as a vote of confidence in Soleno Therapeutics Inc.'s future prospects.
- Increased institutional ownership can sometimes lead to greater market stability and liquidity for the stock.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance from Soleno Therapeutics Inc. or T. Rowe Price Associates, Inc. regarding the issuer's future performance.
Industry Context
This filing indicates a significant institutional investment in Soleno Therapeutics Inc., a company operating in the pharmaceutical/biotechnology sector. Such disclosures are common as large asset managers like T. Rowe Price build positions in publicly traded companies, reflecting their investment strategies and confidence in specific industries or companies.
Stakeholder Impact
- Shareholders may perceive the increased institutional ownership as a positive signal, potentially leading to increased investor confidence and demand for the stock.
- The company's management might view this as validation of their strategy and performance, potentially attracting further institutional interest.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of the event which required the filing of this statement (beneficial ownership threshold crossed). |
| 05/14/2025 | Date the Schedule 13G filing was signed and submitted to the SEC. |
Keywords
Soleno Therapeutics, T. Rowe Price, Schedule 13G, beneficial ownership, institutional investment, common stock, pharmaceuticals, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.